Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

This study tests whether a new drug (tecotabart vedotin) combined with tislelizumab works better than standard chemotherapy plus tislelizumab for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). About 752 adults who have not …

This study is testing a new injection called TQB2825 against standard immunotherapy for people with follicular lymphoma that has returned or hasn't responded to previous treatments. The main goal is to see which treatment keeps the cancer from getting worse for a longer time. Res…